Series: The Whole Child · Part 1 of 4
Autism is diagnosed behaviorally, but many autistic children also live with co-occurring medical conditions — GI pain, fragmented sleep, nutritional deficiencies — that reduce their availability to learn. Acknowledging this doesn’t change what we do as behavior analysts. It changes who we do it with.
Nearly every week we talk with a parent who brings the same concern. Their child is in the program, the team is taking data, there’s progress on some goals. And yet there are days when the child arrives and simply isn’t available. Irritable at stimuli they tolerated yesterday. Refusing tasks they’ve mastered. Three nights of poor sleep, and by the fourth morning the whole plan falls apart.
When that happens, the clinically correct response isn’t always to adjust the reinforcement schedule. Sometimes it’s to ask what’s happening in the body.
Why this is our business (and why only up to a point)
Applied behavior analysis has a precise term for this: a motivating operation of biological origin. Pain, sleep deprivation, digestive discomfort, and illness alter reinforcer value and the probability of problem behavior. They sit outside the contingencies we design, but they run through every session.
When a minimally verbal child cannot report abdominal pain, behavior may be the only signal available. This is not alternative-medicine speculation — it is exactly what the consensus panel of gastroenterologists, neurologists, and developmental pediatricians led by Timothy Buie concluded in Pediatrics in 2010 [1]. GI disorders are common in autistic individuals, they warrant the same medical attention any other child would receive, and in nonverbal children behavioral disturbance may be the only outward manifestation of distress.
Here is the boundary, stated plainly: identifying the possibility of a medical contributor is within our role. Diagnosing it, treating it, or recommending supplements or diets is not. The BACB Ethics Code for Behavior Analysts is explicit in section 2.01 on scope of competence, and standard 2.03 obligates us to refer and collaborate with other professionals when the case requires it. A BCBA recommending a supplement protocol is practicing outside their license; a BCBA who fails to document a behavior pattern consistent with possible pain and communicate it to the family and pediatrician is also not doing the job well.
The practical division. We contribute the data: latency, topography, time-of-day patterns, correlation with meals and sleep, functional assessment results. The physician contributes diagnosis and treatment. The family decides. That’s the interdisciplinary model we pursue in every case.
The actual state of the evidence in 2026
This is where honesty is required, because the autism information space is saturated with promises.
In December 2025, Nature Human Behaviour published the broadest review to date of complementary, alternative, and integrative medicine (CAIM) in autism. Corentin Gosling’s team assessed 248 meta-analyses spanning roughly 200 clinical trials and more than 10,000 participants across 19 common CAIM interventions. Their conclusion was direct: there is no high-quality evidence supporting the efficacy of any CAIM intervention for core or associated autism symptoms. Several showed promising signals, but resting on very low-quality evidence [2]. The group also published an open platform, ebiact-database.com, so families and clinicians can review the evidence intervention by intervention. We recommend it without reservation.
A parallel systematic review by Antonio Persico and colleagues in Progress in Neuro-Psychopharmacology and Biological Psychiatry reviewed 115 randomized controlled trials covering 133 compounds. Their read was somewhat more nuanced, but it should be cited precisely: the authors conclude that clinical use is fully evidence-based only for melatonin (for sleep disturbance), and that for six additional compounds — folinic acid, N-acetylcysteine, L-carnitine, coenzyme Q10, sulforaphane, and metformin — clinical use may be acceptable with caution, but more research is necessary [3].
Editorial accuracy note. We have seen this Persico review cited across several sites as though it declared those six compounds “promising and safe” for clinical use. That reading inflates the evidence level. The only intervention the review treats as fully evidence-based is melatonin. We publish this clarification because families deserve to know the difference between “there’s a signal, more research needed” and “this is established.”
What do we do with this? Two things at once. First, hold without qualification that the interventions with solid support for skill development, communication, and quality of life are behavioral and developmental: ABA, naturalistic developmental behavioral interventions, speech-language pathology, occupational therapy, educational support. Nothing discussed in this series replaces them. Second, don’t confuse “no high-quality evidence for treating autism” with “clinically unimportant.” A child’s chronic constipation does not need a randomized trial in autism to deserve pediatric treatment. It needs a pediatrician.
Five medical areas that recur in the literature
We present these as areas warranting medical evaluation when clinical signs are present — not as a causal model of autism, and not as a list of things to treat. None defines autism and none is present in every child.
1. Gastrointestinal function
A systematic review by Calliope Holingue and colleagues in Autism Research (2018) found that the prevalence of at least one GI symptom in autistic children is estimated between 23% and 70% depending on study design [4]. The range is wide precisely because this is hard to measure; the point is that it isn’t a marginal finding. We cover it in Part 2.
2. Sleep
This is the best-supported area in the entire conversation and, oddly, the least discussed in popular content. Melatonin is the only intervention the Persico review treats as fully evidence-based [3]. For an ABA team, sleep is also the highest-impact motivating operation in practice: a child who slept four hours will not acquire a new skill that day, no matter how well the program is designed.
3. Nutritional status
James Adams and colleagues published a 2011 randomized, double-blind, placebo-controlled trial of a vitamin/mineral supplement in 141 children and adults with autism, with statistically significant improvements on several parent-reported measures [5]. A companion study that year found measurably lower levels of several nutrients versus neurotypical controls [6]. That’s a real signal. It is also a single trial with caregiver-reported primary measures, and any individual child’s nutritional status is determined by lab work, not a blog post.
4. Immune regulation
Immune differences have been documented in subgroups of autistic children. The best-characterized example is folate receptor alpha autoantibodies, reviewed by Daniel Rossignol and Richard Frye in Journal of Personalized Medicine (2021) [7]. We return to this — and to what the FDA actually decided about it — in Part 3.
5. Environmental exposures
Epidemiological studies, including Janie Shelton and colleagues in Environmental Health Perspectives (2014), have associated prenatal residential proximity to agricultural pesticide application with increased neurodevelopmental disorder risk [8]. These are observational studies: they describe association, not individual causation. They’re relevant to public policy and to reasonable family choices, not to explaining any particular child’s diagnosis.
Diet: what can and cannot be said
A randomized, double-blind, placebo-controlled trial published in The Lancet in 2007 by Donna McCann and colleagues tested artificial food colors and sodium benzoate in 297 typically developing British children and found measurable increases in hyperactivity at doses found in everyday foods [9]. It was not a study in autism, and that qualifier matters. But it’s reasonable evidence that certain additives affect children’s behavior generally.
On the gluten-free, casein-free diet, the evidence is genuinely split. The ScanBrit trial by Paul Whiteley and colleagues (2010) found benefits on communication and social interaction subscores at twelve months [10]. Susan Hyman and colleagues (2016), using a double-blind challenge design, found no significant benefit on standardized measures [11]. The Gosling 2025 review places it among interventions without high-quality evidence [2].
Our position as an ABA provider: a child’s dietary decisions belong to the family together with their pediatrician or a registered dietitian nutritionist. What we can offer, and do offer, is what we do best: if your family pursues a clinically supervised dietary trial, our team can collect structured behavioral data across the trial period and the reintroduction. That turns a subjective impression into usable information. We can also target food selectivity as a behavioral goal, which is squarely within our scope.
Clinical note for BCBAs and RBTs
Three operational practices we apply on our cases:
Rule out medical contribution before escalating the behavior plan. With sudden-onset problem behavior, loss of previously mastered skills, self-injury directed at head/abdomen/ears, or behavioral disturbance with a cyclical or postprandial pattern, document the pattern and communicate it to the family with a recommendation for medical evaluation before intensifying reduction procedures. Escalating contingencies against untreated pain is both ineffective and an ethics problem.
Build motivating variables into routine data collection. Sleep hours, bowel movements, illness, new medication or dose change. An ABC record without these leaves out a meaningful share of the variance. The temporal correlation you document may be the most useful thing the pediatrician receives.
Stay in role when communicating. Describe behavior and data; don’t interpret etiology or suggest treatments. Useful framing: “We recorded self-injury directed at the abdomen in 70% of post-lunch sessions over the last three weeks, with no such pattern in morning sessions. We recommend discussing this with your pediatrician.” That satisfies BACB standard 2.03 without crossing into 2.01.
For families: what to bring to the next medical visit
If any of this resonates, the most valuable thing you can do is not to change your child’s diet tomorrow. It’s to walk into the next pediatric appointment with data. Ask your ABA team for a summary of behavioral patterns over the last four to six weeks. Log sleep and bowel movements for two weeks. Note what changed before the behavior changed.
And something we say often in our family meetings: the volume of contradictory information in this field would exhaust anyone, and feeling overwhelmed is not a sign you’re getting it wrong. The reasonable path here is slow, coordinated, and data-driven. Moving deliberately is, in fact, doing this well.
Questions about your child’s program? Our clinical team can meet with you to review your data, discuss goals, and explain how we coordinate with your pediatrician. Call (813) 655-8159 or write to contact@hopefultherapies.com. We serve families in Brandon, Lakeland and Winter Haven, Florida.
About this series. This post discusses and responds to “Beyond Behavior: A Functional Medicine Roadmap for Autism and Childhood Neurodevelopmental Conditions” by Jill Carnahan, MD, published by the Foundation for Alternative and Integrative Medicine. The text on this page is original to Hopeful Therapies. We verified the primary sources the author cites and, where our reading of the evidence differs from hers, we say so explicitly. We recommend reading the original.
References
- Buie T, Campbell DB, Fuchs GJ III, et al. Evaluation, diagnosis, and treatment of gastrointestinal disorders in individuals with ASDs: a consensus report. Pediatrics. 2010;125(Suppl 1):S1-S18. doi:10.1542/peds.2009-1878C
- Gosling CJ, Boisseleau L, Solmi M, et al. Complementary, alternative and integrative medicine for autism: an umbrella review and online platform. Nat Hum Behav. 2025;9(12):2610-2619. nature.com/articles/s41562-025-02256-9
- Persico AM, Asta L, Chehbani F, et al. The pediatric psychopharmacology of autism spectrum disorder: A systematic review — Part II: The future. Prog Neuropsychopharmacol Biol Psychiatry. 2025;136:111176. sciencedirect.com
- Holingue C, Newill C, Lee LC, Pasricha PJ, Fallin MD. Gastrointestinal symptoms in autism spectrum disorder: a review of the literature on ascertainment and prevalence. Autism Res. 2018;11(1):24-36. doi:10.1002/aur.1854
- Adams JB, Audhya T, McDonough-Means S, et al. Effect of a vitamin/mineral supplement on children and adults with autism. BMC Pediatr. 2011;11:111. doi:10.1186/1471-2431-11-111
- Adams JB, Audhya T, McDonough-Means S, et al. Nutritional and metabolic status of children with autism vs. neurotypical children. Nutr Metab (Lond). 2011;8(1):34. doi:10.1186/1743-7075-8-34
- Rossignol DA, Frye RE. Cerebral folate deficiency, folate receptor alpha autoantibodies and leucovorin (folinic acid) treatment in autism spectrum disorders: a systematic review and meta-analysis. J Pers Med. 2021;11(11):1141. PubMed 34834493
- Shelton JF, Geraghty EM, Tancredi DJ, et al. Neurodevelopmental disorders and prenatal residential proximity to agricultural pesticides: the CHARGE study. Environ Health Perspect. 2014;122(10):1103-1109. doi:10.1289/ehp.1307044
- McCann D, Barrett A, Cooper A, et al. Food additives and hyperactive behaviour in 3-year-old and 8/9-year-old children in the community: a randomised, double-blinded, placebo-controlled trial. Lancet. 2007;370(9598):1560-1567. doi:10.1016/S0140-6736(07)61306-3
- Whiteley P, Haracopos D, Knivsberg AM, et al. The ScanBrit randomised, controlled, single-blind study of a gluten- and casein-free dietary intervention for children with autism spectrum disorders. Nutr Neurosci. 2010;13(2):87-100. doi:10.1179/147683010X12611460763922
- Hyman SL, Stewart PA, Foley J, et al. The gluten-free/casein-free diet: a double-blind challenge trial in children with autism. J Autism Dev Disord. 2016;46(1):205-220. doi:10.1007/s10803-015-2564-9
Important notice. Hopeful Therapies provides applied behavior analysis (ABA) services. We are not a medical provider and do not diagnose or treat medical conditions, nor do we prescribe diets, supplements, or medications. This content is educational and does not constitute medical advice or substitute for the relationship with your pediatrician or other qualified health professional. Do not start, stop, or change any treatment, diet, or supplement based on this post. Biomedical interventions mentioned are described solely to inform the conversation between families and their medical team. Our services are delivered in accordance with the BACB Ethics Code for Behavior Analysts and applicable Florida Agency for Health Care Administration (AHCA) requirements. We have no commercial relationship with any supplement manufacturer, laboratory, or testing provider mentioned or linked in this series.
